Recent news updates surrounding Greenwich LifeSciences highlight ongoing patient enrollment and international site expansions for its Phase III FLAMINGO-01 clinical trial evaluating the GP2 immunotherapy. Additionally, market reports have focused on recent sharp stock price fluctuations and thin trading volumes, alongside periodic cash runway updates filed with regulatory authorities as the firm balances its clinical burn rate with capital requirements.